Sotorasib Clinical Trials (2026): 50 Studies for Non-Small Cell Lung Cancer & Healthy Participants

Where to Participate: All Sotorasib Trial Sites in the U.S. (500 sites across 43 states)

Every actively recruiting Sotorasibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Sotorasib clinical trials at a glance: phase × recruitment status

Recruiting Sotorasib clinical trials (17)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Sotorasib clinical trials by indication

Sotorasib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Sotorasib trials (9)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT06068153withdrawnAMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
• NCT05815186withdrawnLadarixin With Sotorasib in Advanced NSCLC - Phase II
• NCT04892017terminatedStudy of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
• NCT06061523withdrawnA Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants
• NCT05480865terminatedSHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
• NCT05400577withdrawnSotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
• NCT05313009terminatedTarlox and Sotorasib in Patients With KRAS G12C Mutations
• NCT05374538terminatedVIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
• NCT05251038withdrawnStudy of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

All Sotorasib trials (50)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Sotorasib clinical trials: frequently asked questions

How many Sotorasib clinical trials are there?

50 Sotorasib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 15 are actively recruiting participants. 13 are marked completed.

Are Sotorasib clinical trials recruiting in 2026?

Yes — 15 Sotorasib trials are actively recruiting in 2026, with 500 U.S. sites across 43 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Sotorasib being studied for?

Sotorasib is being studied for Non-Small Cell Lung Cancer, Healthy Participants, Non Small Cell Lung Cancer, Stage IV Lung Cancer AJCC v8, KRAS P.G12C and 71 more. The trials are grouped by indication on this page.

What phase is Sotorasib in?

Sotorasib clinical trials span 1 Phase 4, 4 Phase 3, 18 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Sotorasib clinical trials?

The lead sponsor across the most Sotorasib trials is Amgen, with 30 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Sotorasibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.